Detalhe da pesquisa
1.
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
Pediatr Blood Cancer
; 71(3): e30817, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38189770
2.
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
Pediatr Blood Cancer
; 70(12): e30672, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37710306
3.
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
Clin Cancer Res
; 28(23): 5088-5097, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36190525
4.
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
Clin Cancer Res
; 28(19): 4173-4177, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679021